* Phase 2 study is underway and LB-P8 is the only live biotherapeutic product currently reported ...
* Co-research and co-development of novel microbiome therapeutics * Discovery of new candidates ...
First Orphan Drug Designation (ODD) in the field of microbiome-based treatment for metabolic diseas...
The efficacy and mechanism of NASH microbiome-based therapy for liver fibrosis, steatosis, and infl...
SEOUL, South Korea, Feb. 3, 2022 /PRNewswire/ -- LISCure Biosciences ("LISCure") announced that it ...
SEOUL, South Korea, Jan. 6, 2022 /PRNewswire/ -- LISCure Biosciences Inc., a leading biotech focuse...
SEOUL, South Korea, Sept. 30, 2021 /PRNewswire/ -- LISCure Biosciences ("LISCure") announced that i...
SEOUL, South Korea, Aug. 1, 2021 /PRNewswire/ -- LISCure Biosciences, Inc. ("LISCure") has entered ...
SEOUL, South Korea, Feb. 26, 2021 /PRNewswire/ -- On February 25th, 2021, LISCure Biosciences Inc.,...
SEOUL, South Korea, July 25, 2019 /PRNewswire/ -- LISCure Biosciences, a biotech company that resea...
